{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:51:51Z","timestamp":1777416711077,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clbc.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T17:15:57Z","timestamp":1339521357000},"page":"247-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases"],"prefix":"10.1016","volume":"12","author":[{"given":"Jipan","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Sorg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Namjoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2012.04.001_bib1","series-title":"Cancer facts and figures 2010","year":"2010"},{"key":"10.1016\/j.clbc.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2012.04.001_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"3 suppl","key":"10.1016\/j.clbc.2012.04.001_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11139","article-title":"Effectiveness and cost of bisphosphonate therapy in tumor bone disease","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2012.04.001_bib6","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib7","first-page":"693","article-title":"Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer","volume":"16","author":"Barlev","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clbc.2012.04.001_bib9","series-title":"Zometa (zoledronic acid) for intravenous infusion","year":"2002"},{"key":"10.1016\/j.clbc.2012.04.001_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2012.04.001_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2012.04.001_bib17","series-title":"Xgeva (denosumab) for subcutaneous injection","year":"2010"},{"key":"10.1016\/j.clbc.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clbc.2012.04.001_bib19","first-page":"1","article-title":"The use of bisphosphonates in cancer treatment","author":"Coleman","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clbc.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","article-title":"Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value","volume":"29","author":"West","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/01.ju.0000116777.94426.60","article-title":"Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer","volume":"171","author":"Reed","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.clbc.2012.04.001_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","article-title":"Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib24","first-page":"621","article-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases","volume":"17","author":"Xie","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clbc.2012.04.001_bib26","series-title":"ReadyPrice","year":"2011"},{"key":"10.1016\/j.clbc.2012.04.001_bib29","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clbc.2012.04.001_bib30","first-page":"47054","article-title":"Medicare Program; changes to the hospital inpatient prospective payment systems and fiscal year 2001 rates","volume":"65","year":"2000","journal-title":"Fed Regist"},{"key":"10.1016\/j.clbc.2012.04.001_bib32","author":"Van Poznak"},{"key":"10.1016\/j.clbc.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.27_suppl.294","article-title":"Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC)","volume":"29","author":"Carter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","article-title":"Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value","volume":"29","author":"West","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2012.04.001_bib36","first-page":"43754","article-title":"Medicare Program; changes to the hospital inpatient prospective payment systems for acute care hospitals and fiscal year 2010 rates; and changes to the long-term care hospital prospective payment system and rate years 2010 and 2009 rates","volume":"74","year":"2009","journal-title":"Fed Regist"},{"key":"10.1016\/j.clbc.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.2337\/diacare.27.12.2829","article-title":"End-stage renal disease-associated managed care costs among patients with and without diabetes","volume":"27","author":"Joyce","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clbc.2012.04.001_bib40","series-title":"Dental use, expenses, private dental coverage, and changes, 1996 and 2004","author":"Manski","year":"2007"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820912000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820912000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:04:31Z","timestamp":1761512671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820912000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1526820912000882"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2012.04.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2012.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}